Although the association of ABCG2 polymorphism with drug resistance has been addressed in a range of solid tumors including lung cancer 5, 10-13, its relevance in outcome prediction for platinum-based chemotherapy of NSCLC is still elusive, and particularly, pharmacogenetic interaction between platinum uptake and efflux transporter genes is largely unknown. This evidence concerns the gene ABCG2 and lung carcinoma.